<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00636207</url>
  </required_header>
  <id_info>
    <org_study_id>0476-380</org_study_id>
    <secondary_id>2008_516</secondary_id>
    <nct_id>NCT00636207</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)</brief_title>
  <official_title>A Sequential, 3-Part, Double-Blind, Randomized, Placebo-Controlled, Single-Rising-Dose and Rising-Multiple-Dose Study in Healthy Subjects and Mild or Moderate Asthmatic Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled MK-0476</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study to evaluate the safety, tolerability and pharmacokinetics of inhaled Montelukast
      (MK-0476) in participants with mild or moderate asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced At Least One Adverse Event</measure>
    <time_frame>Up to 14 days after last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 7 days after last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From 0 to 24 Hours (AUC 0-24hr) of Montelukast - Single Dose</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
    <description>Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-24hr of Montelukast - Multiple Doses</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
    <description>Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Montelukast - Single Dose</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
    <description>Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Montelukast - Multiple Doses</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
    <description>Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of Montelukast - Single Dose</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
    <description>Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Montelukast - Multiple Doses</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
    <description>Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half Life (t1/2) of Montelukast - Single Dose</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
    <description>Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Montelukast - Multiple Doses</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
    <description>Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-24hr Accumulation Ratio of Montelukast - Multiple Doses</measure>
    <time_frame>up to 10 days after first dose of study drug</time_frame>
    <description>The AUC 0-24hr Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of AUC 0-24hr on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Accumulation Ratio of Montelukast - Multiple Doses</measure>
    <time_frame>up to 10 days after first dose of study drug</time_frame>
    <description>The Cmax Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of Cmax on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Montelukast 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Montelukast inhalation powder, 0.1 mg.
Part I: Administered as a single dose followed by at least a 3-day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast 0.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Montelukast inhalation powder, 0.3 mg.
Part I: Administered as a single dose followed by at least a 3-day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Montelukast inhalation powder, 1 mg.
Part I: Administered as a single dose followed by at least a 3-day washout period.
Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Montelukast inhalation powder, 3 mg.
Part I: Administered as a single dose followed by at least a 3-day washout period.
Part II: Administered QD for 5 days followed by at least a 3-day washout period.
Part III: Administered QD for 10 days followed by at least a 7-day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Montelukast inhalation powder, 10 mg.
Part I: Administered as a single dose followed by at least a 3-day washout period.
Part II: Administered QD for 5 days followed by at least a 3-day washout period.
Part III: Administered QD for 10 days followed by at least a 7-day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive Placebo to Montelukast inhalation powder.
Part I: Administered as a single dose followed by at least a 3-day washout period.
Part II: Administered QD for 5 days followed by at least a 3-day washout period.
Part III: Administered QD for 10 days followed by at least a 7-day washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg</description>
    <arm_group_label>Montelukast 0.1 mg</arm_group_label>
    <arm_group_label>Montelukast 0.3 mg</arm_group_label>
    <arm_group_label>Montelukast 1 mg</arm_group_label>
    <arm_group_label>Montelukast 3 mg</arm_group_label>
    <arm_group_label>Montelukast 10 mg</arm_group_label>
    <other_name>Montelukast Sodium</other_name>
    <other_name>MK-0476</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dry powder inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the ages of 18 and 65

          -  Must have mild or moderate asthma (Part III only)

          -  Nonsmoker for at least 6 months

        Exclusion Criteria:

          -  History of stroke, chronic seizures or major neurological disorder

          -  You are nursing

          -  Drink more than 3 glasses of alcohol a day

          -  Have allergy to or not able to tolerate lactose

          -  Have a history of drug abuse in the last 5 years

          -  Drink more than 6 beverages containing caffeine a day

          -  Have had surgery, donated blood or participated in another investigational study in
             the last 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>March 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <results_first_submitted>December 20, 2012</results_first_submitted>
  <results_first_submitted_qc>December 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2013</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 3 study sites located in the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part I - Montelukast</title>
          <description>Part I consisted of 6 periods. Participants were to receive single doses of inhaled Montelukast (0.1 mg, 0.3 mg, 0.3 mg repeat, 1 mg, 3 mg or 10 mg). Each dose was separated by at least a 3-day washout period.</description>
        </group>
        <group group_id="P2">
          <title>Part I - Montelukast and Placebo</title>
          <description>Part I consisted of 6 periods. Participants were to receive single doses of inhaled Montelukast (0.1 mg, 0.3 mg, 0.3 mg repeat, 1 mg, 3 mg or 10 mg) or Placebo. Each dose was separated by at least a 3-day washout period.</description>
        </group>
        <group group_id="P3">
          <title>Part II - Montelukast</title>
          <description>Part II consisted of 3 periods. Participants in three serial panels (Panels A, B and C) were to receive once daily (QD) doses of inhaled Montelukast (1 mg, 3 mg or 10 mg) administered for 5 consecutive days. Each panel was separated by at least a 3-day washout period.</description>
        </group>
        <group group_id="P4">
          <title>Part II - Placebo</title>
          <description>Part II consisted of 3 periods. Participants in three serial panels (Panels A, B and C) were to receive QD doses of inhaled Placebo administered for 5 consecutive days. Each panel was separated by at least a 3-day washout period.</description>
        </group>
        <group group_id="P5">
          <title>Part III - Montelukast</title>
          <description>Part III consisted of 2 periods. Participants in two serial panels (Panels A and B) were to receive QD doses of inhaled Montelukast (3 mg or 10 mg) administered for 10 consecutive days. Each panel was separated by at least a 7-day washout period.</description>
        </group>
        <group group_id="P6">
          <title>Part III - Montelukast and Placebo</title>
          <description>Part III consisted of 2 periods. Participants in two serial panels (Panels A and B) were to receive QD doses of inhaled Montelukast (3 mg or 10 mg) or Placebo administered for 10 consecutive days. Each panel was separated by at least a 7-day washout period.</description>
        </group>
        <group group_id="P7">
          <title>Part III - Placebo</title>
          <description>Part III consisted of 2 periods. Participants in two serial panels (Panels A and B) were to receive QD doses of inhaled or Placebo administered for 10 consecutive days. Each panel was separated by at least a 7-day washout period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1">One participant discontinued after completing Period 2. Doses in Periods 1 and 2 were Montelukast.</participants>
                <participants group_id="P2" count="8">One participant withdrew consent after completing all study doses.</participants>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="9">One participant withdrew consent after completing all study doses.</participants>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part I</title>
          <description>Part I consisted of 6 periods. Participants were to receive single doses of inhaled Montelukast (0.1 mg, 0.3 mg, 0.3 repeat, 1 mg, 3 mg or 10 mg) or Placebo. Each dose was separated by at least a 3-day washout period.</description>
        </group>
        <group group_id="B2">
          <title>Part II</title>
          <description>Part II consisted of 3 periods. Participants in three serial panels (Panels A, B and C) were to receive once daily (QD) doses of inhaled Montelukast (1 mg, 3 mg or 10 mg) or Placebo administered for 5 consecutive days. Each panel was separated by at least a 3-day washout period.</description>
        </group>
        <group group_id="B3">
          <title>Part III</title>
          <description>Part III consisted of 2 periods. Participants in two serial panels (Panels A and B) were to receive QD doses of inhaled Montelukast (3 mg or 10 mg) or Placebo administered for 10 consecutive days. Each panel was separated by at least a 7-day washout period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4" spread="10.45"/>
                    <measurement group_id="B2" value="31.0" spread="12.68"/>
                    <measurement group_id="B3" value="36.3" spread="10.32"/>
                    <measurement group_id="B4" value="33.8" spread="11.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced At Least One Adverse Event</title>
        <time_frame>Up to 14 days after last dose of study drug</time_frame>
        <population>Safety Population: All participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 0.1 mg</title>
            <description>Participants receiving Montelukast 0.1 mg inhalation powder</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 0.3 mg</title>
            <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder</description>
          </group>
          <group group_id="O4">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder</description>
          </group>
          <group group_id="O5">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants receiving Placebo inhalation powder</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced At Least One Adverse Event</title>
          <population>Safety Population: All participants who received at least one dose of study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Drug Due to an Adverse Event</title>
        <time_frame>Up to 7 days after last dose of study drug</time_frame>
        <population>Safety Population: All participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 0.1 mg</title>
            <description>Participants receiving Montelukast 0.1 mg inhalation powder</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 0.3 mg</title>
            <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder</description>
          </group>
          <group group_id="O4">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder</description>
          </group>
          <group group_id="O5">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants receiving Placebo inhalation powder</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Drug Due to an Adverse Event</title>
          <population>Safety Population: All participants who received at least one dose of study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From 0 to 24 Hours (AUC 0-24hr) of Montelukast - Single Dose</title>
        <description>Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
        <time_frame>Up to 24 hours postdose</time_frame>
        <population>Per Protocol Population: All participants who complied with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 0.1 mg</title>
            <description>Participants receiving Montelukast 0.1 mg inhalation powder</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 0.3 mg</title>
            <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 0.3 mg Repeat</title>
            <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
          </group>
          <group group_id="O4">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder</description>
          </group>
          <group group_id="O5">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder</description>
          </group>
          <group group_id="O6">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From 0 to 24 Hours (AUC 0-24hr) of Montelukast - Single Dose</title>
          <description>Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
          <population>Per Protocol Population: All participants who complied with the protocol</population>
          <units>ng/mL*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Plasma level below lower limit of quantitation</measurement>
                    <measurement group_id="O2" value="NA">Plasma level below lower limit of quantitation</measurement>
                    <measurement group_id="O3" value="NA">Plasma level below lower limit of quantitation</measurement>
                    <measurement group_id="O4" value="155" spread="18.5"/>
                    <measurement group_id="O5" value="491" spread="71"/>
                    <measurement group_id="O6" value="1600" spread="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0-24hr of Montelukast - Multiple Doses</title>
        <description>Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
        <time_frame>Up to 24 hours postdose</time_frame>
        <population>Per Protocol Population: All participants who complied with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder QD</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder QD</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder QD</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-24hr of Montelukast - Multiple Doses</title>
          <description>Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
          <population>Per Protocol Population: All participants who complied with the protocol</population>
          <units>ng/mL*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part II Day 1 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" spread="43.7"/>
                    <measurement group_id="O2" value="403" spread="115"/>
                    <measurement group_id="O3" value="1576" spread="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part II Day 5 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" spread="76.3"/>
                    <measurement group_id="O2" value="576" spread="148"/>
                    <measurement group_id="O3" value="1850" spread="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III Day 1 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not obtained in Part III</measurement>
                    <measurement group_id="O2" value="357" spread="109"/>
                    <measurement group_id="O3" value="1500" spread="521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III Day 10 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not obtained in Part III</measurement>
                    <measurement group_id="O2" value="526" spread="133"/>
                    <measurement group_id="O3" value="1880" spread="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Montelukast - Single Dose</title>
        <description>Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
        <time_frame>Up to 24 hours postdose</time_frame>
        <population>Per Protocol Population: All participants who complied with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 0.1 mg</title>
            <description>Participants receiving Montelukast 0.1 mg inhalation powder</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 0.3 mg</title>
            <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 0.3 mg Repeat</title>
            <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
          </group>
          <group group_id="O4">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder</description>
          </group>
          <group group_id="O5">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder</description>
          </group>
          <group group_id="O6">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Montelukast - Single Dose</title>
          <description>Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
          <population>Per Protocol Population: All participants who complied with the protocol</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Plasma level below lower limit of quantitation</measurement>
                    <measurement group_id="O2" value="5.10" spread="0.977"/>
                    <measurement group_id="O3" value="5.24" spread="0.914"/>
                    <measurement group_id="O4" value="18.5" spread="4.15"/>
                    <measurement group_id="O5" value="54.3" spread="12.7"/>
                    <measurement group_id="O6" value="224" spread="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Montelukast - Multiple Doses</title>
        <description>Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
        <time_frame>Up to 24 hours postdose</time_frame>
        <population>Per Protocol Population: All participants who complied with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder QD</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder QD</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder QD</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Montelukast - Multiple Doses</title>
          <description>Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
          <population>Per Protocol Population: All participants who complied with the protocol</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part II Day 1 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="4.96"/>
                    <measurement group_id="O2" value="60" spread="13.1"/>
                    <measurement group_id="O3" value="233" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part II Day 5 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="6.5"/>
                    <measurement group_id="O2" value="76" spread="15.3"/>
                    <measurement group_id="O3" value="242" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III Day 1 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not obtained in Part III</measurement>
                    <measurement group_id="O2" value="44.3" spread="16.6"/>
                    <measurement group_id="O3" value="184" spread="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III Day 10 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not obtained in Part III</measurement>
                    <measurement group_id="O2" value="64.8" spread="13.0"/>
                    <measurement group_id="O3" value="225" spread="84.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Cmax (Tmax) of Montelukast - Single Dose</title>
        <description>Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
        <time_frame>Up to 24 hours postdose</time_frame>
        <population>Per Protocol Population: All participants who complied with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 0.1 mg</title>
            <description>Participants receiving Montelukast 0.1 mg inhalation powder</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 0.3 mg</title>
            <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 0.3 mg Repeat</title>
            <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
          </group>
          <group group_id="O4">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder</description>
          </group>
          <group group_id="O5">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder</description>
          </group>
          <group group_id="O6">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of Montelukast - Single Dose</title>
          <description>Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
          <population>Per Protocol Population: All participants who complied with the protocol</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Plasma level below lower limit of quantitation</measurement>
                    <measurement group_id="O2" value="2.5" lower_limit="0.8" upper_limit="4.0"/>
                    <measurement group_id="O3" value="4.0" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O4" value="2.4" lower_limit="0.5" upper_limit="7.0"/>
                    <measurement group_id="O5" value="0.8" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Montelukast - Multiple Doses</title>
        <description>Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
        <time_frame>Up to 24 hours postdose</time_frame>
        <population>Per Protocol Population: All participants who complied with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder QD</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder QD</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder QD</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Montelukast - Multiple Doses</title>
          <description>Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
          <population>Per Protocol Population: All participants who complied with the protocol</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part II Day 1 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.7" upper_limit="7"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.5" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part II Day 5 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.5" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.5" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.5" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III Day 1 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not obtained in Part III</measurement>
                    <measurement group_id="O2" value="0.5" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.2" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III Day 10 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not obtained in Part III</measurement>
                    <measurement group_id="O2" value="0.5" lower_limit="0.2" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half Life (t1/2) of Montelukast - Single Dose</title>
        <description>Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
        <time_frame>Up to 24 hours postdose</time_frame>
        <population>Per Protocol Population: All participants who complied with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 0.1 mg</title>
            <description>Participants receiving Montelukast 0.1 mg inhalation powder</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 0.3 mg</title>
            <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 0.3 mg Repeat</title>
            <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
          </group>
          <group group_id="O4">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder</description>
          </group>
          <group group_id="O5">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder</description>
          </group>
          <group group_id="O6">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half Life (t1/2) of Montelukast - Single Dose</title>
          <description>Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.</description>
          <population>Per Protocol Population: All participants who complied with the protocol</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Plasma level below lower limit of quantitation</measurement>
                    <measurement group_id="O2" value="NA">Plasma level below lower limit of quantitation</measurement>
                    <measurement group_id="O3" value="NA">Plasma level below lower limit of quantitation</measurement>
                    <measurement group_id="O4" value="5.7" spread="2.1"/>
                    <measurement group_id="O5" value="6.9" spread="0.9"/>
                    <measurement group_id="O6" value="5.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of Montelukast - Multiple Doses</title>
        <description>Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
        <time_frame>Up to 24 hours postdose</time_frame>
        <population>Per Protocol Population: All participants who complied with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder QD</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder QD</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder QD</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Montelukast - Multiple Doses</title>
          <description>Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.</description>
          <population>Per Protocol Population: All participants who complied with the protocol</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part II Day 5 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.5"/>
                    <measurement group_id="O2" value="7.6" spread="2.5"/>
                    <measurement group_id="O3" value="7.7" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III Day 10 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not obtained in Part III</measurement>
                    <measurement group_id="O2" value="8.1" spread="1.4"/>
                    <measurement group_id="O3" value="7.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0-24hr Accumulation Ratio of Montelukast - Multiple Doses</title>
        <description>The AUC 0-24hr Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of AUC 0-24hr on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.</description>
        <time_frame>up to 10 days after first dose of study drug</time_frame>
        <population>Per Protocol Population: All participants who complied with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder QD</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder QD</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder QD</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-24hr Accumulation Ratio of Montelukast - Multiple Doses</title>
          <description>The AUC 0-24hr Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of AUC 0-24hr on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.</description>
          <population>Per Protocol Population: All participants who complied with the protocol</population>
          <units>ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part II (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61"/>
                    <measurement group_id="O2" value="1.44"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not obtained in Part III</measurement>
                    <measurement group_id="O2" value="1.19"/>
                    <measurement group_id="O3" value="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax Accumulation Ratio of Montelukast - Multiple Doses</title>
        <description>The Cmax Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of Cmax on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.</description>
        <time_frame>up to 10 days after first dose of study drug</time_frame>
        <population>Per Protocol Population: All participants who complied with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 1 mg</title>
            <description>Participants receiving Montelukast 1 mg inhalation powder QD</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 3 mg</title>
            <description>Participants receiving Montelukast 3 mg inhalation powder QD</description>
          </group>
          <group group_id="O3">
            <title>Montelukast 10 mg</title>
            <description>Participants receiving Montelukast 10 mg inhalation powder QD</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax Accumulation Ratio of Montelukast - Multiple Doses</title>
          <description>The Cmax Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of Cmax on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.</description>
          <population>Per Protocol Population: All participants who complied with the protocol</population>
          <units>ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part II (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73"/>
                    <measurement group_id="O2" value="1.27"/>
                    <measurement group_id="O3" value="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not obtained in Part III</measurement>
                    <measurement group_id="O2" value="1.03"/>
                    <measurement group_id="O3" value="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after last dose of study drug</time_frame>
      <desc>Safety Population: All participants who received at least one dose of study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>Montelukast 0.1 mg</title>
          <description>Participants receiving Montelukast 0.1 mg inhalation powder</description>
        </group>
        <group group_id="E2">
          <title>Montelukast 0.3 mg</title>
          <description>Participants receiving Montelukast 0.3 mg inhalation powder</description>
        </group>
        <group group_id="E3">
          <title>Montelukast 1 mg</title>
          <description>Participants receiving Montelukast 1 mg inhalation powder</description>
        </group>
        <group group_id="E4">
          <title>Montelukast 3 mg</title>
          <description>Participants receiving Montelukast 3 mg inhalation powder</description>
        </group>
        <group group_id="E5">
          <title>Montelukast 10 mg</title>
          <description>Participants receiving Montelukast 10 mg inhalation powder</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Participants receiving Placebo inhalation powder</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Paraesthesia Oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President,Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

